112733-45-6Relevant articles and documents
The process development of a novel aldose reductase inhibitor, FK366. Part 1. Improvement of discovery process and new syntheses of 1-substituted quinazolinediones
Goto, Shunsuke,Tsuboi, Hiroyuki,Kanoda, Masami,Mukai, Koji,Kagara, Kooji
, p. 700 - 706 (2013/09/05)
This contribution describes part 1 of process development of a novel aldose reductase inhibitor FK366 (1). The original process applied on a laboratory scale was improved from the safety viewpoint to manufacture materials on 500-L scale suitable for toxic
Process for producing quinazoline derivatives
-
, (2008/06/13)
A process for producing 1,2,3,4-tetrahydro-2,4-dioxo-quinazoline-1-yl acetic acid derivatives of the formula (I) in which R1, R2, R3 and R4 are mutually independently hydrogen, halogen, OH, NO2, (C1 -C6) alkoxy, (C1 -C6) alkyl, halogen-substituted (C1 -C6) alkyl, R5 is hydrogen, (C1 -C6) alkyl, phenyl where the alkyl or phenyl radical may also be substituted by halogen atoms; in which an anthranilic acid derivative of formula (II), in which R1 to R5 have the above meaning and R6 is hydrogen, (C1 -C6) alkyl or phenyl, where the alkyl or phenyl radical may also be substituted by halogen atoms, is reacted with a metal cyanate and hydrogen chloride in the presence of an inert solvent. STR1
Quinazoline derivatives, compositions thereof and their use in treating diabetic complications
-
, (2008/06/13)
The invention relates to compounds of the formula: STR1 in which R1 and R2 are each hydrogen, halogen, lower alkoxy or halo(lower)alkyl, R3 is dihalophenyl, naphthyl(lower)alkyl, phenyl(lower)alkyl substituted by one or two substituent(s) selected from the group consisting of halogen, lower alkoxy, halo(lower)alkyl and lower alkyl, or thienyl(lower)alkyl, R4 is carboxy or protected carboxy, Y is carbonyl, thiocarbonyl or sulfonyl and Z is lower alkylene, and pharmaceutically acceptable salts thereof, useful in the treatment of diabetic complications.